Dr. Anjani Jha is the President and CEO of MAA Laboratories and has a deep understanding of the pharmaceutical business. He has extensive experience in drug and technology development at Pii, MIT, GSK, and Rhodes and has worked with small molecules in various therapeutic classes and dosage forms from the preclinical stage to commercialization. Dr. Jha has launched several products in the areas of anti-cancer, anti-inflammatory, hypertension, respiratory, pain management, and ADHD using nano drug delivery and continuous manufacturing approaches. At the Novartis-MIT Center, he was involved in the development and integration of the first end-to-end continuous manufacturing process for pharmaceuticals. In addition to industry experience of increasing responsibility, Dr. Jha formed and led teams through student leadership activities. He has completed his Post-doctoral work from the Massachusetts Institute of Technology (MIT) and received a PhD from Pennsylvania State University. Dr. Jha is also an alumnus of Indian Institute of Technology Kharagpur.
Mr. Ed Bogart brings over 36 years of experience in the healthcare industry, advancing pharmaceuticals, biologics, and medical devices in the United States and Internationally. Mr. Bogart has held numerous executive positions in Pharmaceutical, Biopharma, Medical Device, USAF Medical Corps, companies’ with an expertise in the areas of pharmaceutical sales, hospital sales, academic medicine, government accounts (nationally & internationally),managed care, regional and national accounts, product management, product launches (IND, 505(b)(2), reformulations, and orphan), new product launches, pharmaco-economics, health outcomes/health economics (data modeling), clinical trail funding/sourcing, contract department design/buildout and management. Price analytics, price scheduling, negotiations across all business segments for market access. Specialized in working with all government agencies (DoD, CMS, CDC, & VA Health System). Mr. Bogart possesses a thorough understanding of every aspect of reimbursement strategies. Mr. Bogart received a BS in Healthcare Administration Management from Park University in Parkville, MO.
Dr. Honoré is currently serving as the President of Aestus Partners. He is also serving as the founding member of the scientific advisory board at Forge Life Science and chairman of the board Dep-Xplora Aps and previously served as Vice President of Discovery Research. Dr. Honore also served as the Senior Executive Vice President at Novartis. Before Novartis, he served as the Vice President of Discovery Research at Novo Nordisk. As a pharma executive, Dr. Honore championed development of ideas to early clinical studies in cancer immunotherapy, alzheimer’s disease, anxiety, chronic pain, depression, epilepsy, female hormone replacement therapy, learning disorders, osteoporosis, Parkinson’s disease, stroke and schizophrenia. Dr. Honore contributed to more than 40 new molecular entities entering clinical development of which three were launched, and he managed budgets for a total of approximately $1B. Dr. Honore developed organizational models to obtain record pipeline productivity in several companies and entrepreneurial value creation by integration of research, clinical, marketing and financial stakeholders. He published more than 100 scientific journal articles and is an inventor on 23 patents. His Doctoral degrees in Medicinal Chemistry and Neurobiology and business training are from Harvard Business School and European Management Centre.
Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development at Amneal Pharmaceuticals. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.
Mr. Disbrow is currently serving as the Chief Operating Officer at Aytu BioScience. Mr. Disbrow previously served as President & CEO of Vyrix Pharmaceuticals since November 2013 until the merger to form Aytu BioScience in April 2015. Mr. Disbrow has over eighteen years of experience in the pharmaceutical industry with “Big Pharma” and specialty pharmaceutical companies and was the Founder, President and Chief Executive Officer of Arbor Pharmaceuticals – a specialty pharmaceutical company focused initially on pediatrics. As the sole founder of Arbor he was responsible for all aspects of the company’s start-up and growth phases including fundraising, business and product development, commercial strategy, product marketing and partnering. He was also responsible for negotiating the acquisition of the company to a private investor group in 2010 and remained with the company, post-acquisition, as Vice President of Commercial Development. In less than five years Arbor grew from a company with no product revenues to net sales in excess of $127 million. Prior to founding Arbor Pharmaceuticals, he was head of marketing for Accentia Biopharmaceuticals, Inc. Mr. Disbrow began his career with GlaxoWellcome, Inc. (now GlaxoSmithKline plc) where he held positions of increasing responsibility in sales and marketing. He received a BS in Business Management from North Carolina State University in Raleigh, NC.
Mr. Golden is an analytical chemist with over 35 years of experience in the pharmaceutical industry, with extensive experience in product development and regulatory affairs. Prior to forming Golden Regulatory Consulting in 2019, Mr. Golden worked for Pearl Therapeutics as part of the executive team where he established the Regulatory Affairs and Quality departments that were involved with development and global registration of Bevespi Aerosphere. After Pearl Therapeutics was acquired by AstraZeneca, he managed a group of Regulatory Affairs professionals that supported global registration of the AstraZeneca respiratory portfolio, including small molecule and biologic products. He also worked at Glaxo Smith Kline as a product development team leader for respiratory products and then as a member of the CMC Regulatory team and was involved with registration of multiple inhalation products. Prior to Glaxo Smith Kline, he worked for The Upjohn Company and was involved with bioavailability testing and process analytical chemistry. He received a BS in chemistry and an MS in Analytical Chemistry from the University of Georgia.
Dr. Tehrani oversees the Hospitalist programs at UNC REX Healthcare in Raleigh N.C., Wayne Memorial Hospital in Goldsboro, N.C., and Johnston Health’s hospitals in Smithfield, N.C. and Clayton, N.C. Dr. Tehrani has expertise in length of stay management, hospitalist staffing models, patient satisfaction, and quality improvements. Dr. Tehrani has served on numerous medical staff committees and is the past Chairman of the Department of Medicine and former Medical Director of Information Technology at UNC REX Healthcare. Dr. Tehrani is a board member of the REX Health Ventures, an innovation platform that fosters new technologies and companies in the healthcare sector. Dr. Tehrani completed his executive MBA from University of North Carolina, Chapel Hill and MD from George Washington University.